



2024 Global Labeling & Regulatory Symposium

Developed and presented in partnership with Opus Regulatory

October 8 - 9, 2024

Kimpton Hotel Monaco – Washington, DC

Course Description

This is a one-of-a-kind comprehensive labeling education symposium that explores both fundamental labeling skills and specialized concepts, including current events and new regulatory initiatives. Throughout the two-day program, global experts from big pharma and small pharma will lead several dynamic sessions; faculty for this program also include current and former FDA representatives, academics, and consultant presenters. The program features a blend of interactive presentations, panel discussions, case studies, and collaborative sessions, each meticulously planned to provide the best experience for symposium participants.

Course Day 1: Tuesday, October 8, 2024

#

7:30 – 8:30 AM

Check in & Continental Breakfast

8:30 – 8:45 AM

Welcome Remarks

8:45 – 10:10 AM

Establishing Labeling Governance and Process

S1

8:50 – 9:10 AM

Presentation: Small Pharma – No Labeling Presence**Jody L Roth, PMP, RAC**Senior Vice President Global Regulatory Affairs
Immunovant

9:10 – 9:30 AM

Presentation: Medium Pharma – Establishing Labeling Model**Christina McGahan**Senior Director, Global Labeling
Otsuka Pharmaceutical Development & Commercialization

9:30 – 9:50 AM

Presentation: Large Pharma – “Well Oiled Machine”**Kelly Treonze**Executive Director, Global Labeling Therapeutic Areas
Merck & Co., Inc.

9:50 – 10:10 AM

Panel Q&A

10:10 – 10:25 AM

Stretch Break

Course Day 1: Tuesday, October 8, 2024 *continued*

10:25 – 11:45 AM	<u>Patient-Reported Outcomes & Real-World Evidence in Labeling</u>	S2
10:30 – 10:50 AM	Presentation: Case Study: FDA Review of RWE in Breast Cancer Therapy	
	Catherine Lerro, PhD, MPH Senior Pharmacoepidemiologist Oncology Center of Excellence US Food and Drug Administration	
10:50 – 11:10 AM	Presentation: Academic Perspective: Patient-Reported Outcomes in Labeling	
	Ari Gnanasakthy, MBA, MSc Principal Scientist, Patient-Centered Outcome Assessment RTI Health Solutions	
11:10 – 11:30 AM	Presentation: FDA Perspective/Update on Patient-Reported Outcomes	
	Vishal Bhatnagar, MD Associate Director, Patient Outcomes Oncology Center of Excellence US Food and Drug Administration	
11:30 AM – 11:45 AM	Panel Q&A	
11:45 – 11:55 AM	Stretch Break	
11:55 AM – 1:15 PM	<u>Labeling Lifecycle Concepts</u>	S3
12:00 – 12:20 PM	Presentation: What is End-to-End Labeling – How Does It Evolve?	
	Vijay Sammeta, MD, MBA Head, Global Regulatory Affairs Labeling Daiichi Sankyo	
12:20 – 12:40 PM	Presentation: Deviation Management and Tracking Tools	
	Kelly Treonze Executive Director, Global Labeling Therapeutic Areas Merck & Co., Inc.	
12:40 – 1:00 PM	Presentation: Preparing for the World of E-Labeling	
	Sima Desai Senior Director Global Labeling Sanofi	
1:00 – 1:15 PM	Panel Q&A	
1:15 – 2:30 PM	<u>Networking Luncheon</u>	

Course Day 1: Tuesday, October 8, 2024 *continued*

2:30 – 3:50 PM **The Importance of Development Labeling** **S4**

2:35 – 2:55 PM **Presentation:** Labeling Perspective on TPL – *When should it start, Who is responsible, How is it done (example)*

Vijay Sammeta, MD, MBA

Head, Global Regulatory Affairs Labeling
Daiichi Sankyo

2:55 – 3:15 PM **Presentation:** TPL in Phase II – Impact to Protocol Development and SAP

Heather Hammond, BPharm, MSc

Director, Regulatory Labeling
Regeneron

3:15 – 3:35 PM **Presentation:** Label as Driver Case Study – *The evolution of label messaging. How did we start and where did we land?*

Thomas Kilker

Director, Regulatory Affairs Labeling
Jazz Pharmaceuticals

3:35 – 3:50 PM **Panel Q&A**

3:50 – 4:05 PM **Stretch Break**

4:05 – 5:25 PM **FDA Key Labeling Initiatives** **S5**

4:10 – 4:40 PM **Presentation:** Oncology Center of Excellence (OCE) Updates / Labeling Initiatives (Project Renewal, Oncology Labeling Priorities)

William Pierce, PharmD, MPH, BCPS

Associate Director, Oncology Labeling
Oncology Center of Excellence
US Food and Drug Administration

4:40 – 5:25 PM **FDA Panel Discussion / Q&A**

Doris Auth

Vishal Bhatnagar, MD

Catherine Lerro, PhD, MPH

William Pierce, PharmD, MPH, BCPS

US Food and Drug Administration

5:25 – 5:30 PM **Closing Remarks: Day 1**

6:00 – 7:30 PM

**Optional*

Evening Networking Reception

Paris Ballroom, Hotel Monaco

Join us for drinks and hors d'oeuvres after a long day of learning! Relax and mingle with participants and faculty, as well as connect with representatives from Docuvera, one of our supporting sponsors.

Course Day 2: Wednesday, October 9, 2024

7:30 – 8:30 AM	<u>Check in & Continental Breakfast</u>	
8:30 – 8:40 AM	<u>Welcome Remarks</u>	
8:40 – 10:00 AM	<u>Labeling for Challenging Populations</u>	S6
8:45 – 9:05 AM	Presentation: Pediatrics Case Study - Impact to Labeling	
	Laurie Cooker, PhD Director, Strategic Global Labeling AbbVie	
9:05 – 9:25 AM	Presentation: Rare Disease Case Study	
	Kathy Bradley Global Labeling Director AstraZeneca	
9:25 - 9:45 AM	Presentation: Companion Diagnostics – Global Case Study	
	Heather Hammond, BPharm, MSc Director, Regulatory Labeling Regeneron	
9:45 – 10:00 AM	Panel Q&A	
10:00 – 10:20 AM	<u>Morning Break</u>	
10:20 – 11:40 AM	<u>Oncology Safety Labeling</u>	S7
10:25 – 10:55 AM	Presentation: Oncology Overview of FDA Adverse Reaction Guidance for SARs, Dosage Modifications, and Low Incidence Adverse Reactions	
	William Pierce, PharmD, MPH, BCPS Associate Director, Oncology Labeling Oncology Center of Excellence, US Food and Drug Administration	
10:55 – 11:25 AM	Presentation: Local Country Labeling Impact to Company Core Data Sheet	
	Mark A. Smith Director, Global Labeling Strategy Bristol Myers Squibb	
11:25 – 11:40 AM	Panel Q&A	

Course Day 2: Wednesday, October 9, 2024 *continued*

- 11:40 – 11:50 AM **Stretch Break**
- 11:50 AM – 1:10 PM **Instructions for Use Labeling** **S8**
- 11:55 AM – 12:25 PM **Presentation:** IFU as Global Labeling Document and Human Factor Testing
- Gerrit Nijveldt**
Principal Labeling Consultant
Opus Regulatory, Inc.
- 12:25 – 12:55 PM **Presentation:** Instructions for Use Labeling Case Study
- Mike Fahmy**
Executive Director
Otsuka Pharmaceutical Development & Commercialization
- 12:55 – 1:10 PM **Panel Q&A**
- 1:10 – 2:25 PM **Networking Luncheon**
- 2:25 – 3:50 PM **Label Negotiations** **S9**
- 2:30 – 3:00 PM **Presentation:** FDA Perspective: *How are labeling negotiations managed, Advice to sponsor, Roles and responsibilities*
- Doris Auth, PharmD**
Associate Director for Labeling
Oncology Center of Excellence
US Food and Drug Administration
- 3:00 – 3:30 PM **Presentation:** Industry perspective: *Preparing and managing label negotiations, best practices, and common considerations*
- Jamie Park**
Global Labeling Lead
Pfizer
- 3:30 – 3:50 PM **Panel Q&A**
- 3:50 – 4:00 PM **Program Wrap Up & Conclusion**